Former Woodford favourite Mereo Biopharma: they marched it up to the top of the hill……

……And they marched it down again. Woodford dog-pick extraordinaire, Aim- and Nasdaq- listed  Mereo Biopharma (AIM: MPH, Nasdaq: MREO) announced what appeared to be good news yesterday, sending the AIM-listed shares up from 33p as high as 45.5p before they fell back down to 38p at the close yesterday. Meanwhile the Nasdaq stock put on around 48% at the peak, before giving up almost the entire gain to close up just 7%. The news was not so good after all!...

BREAKING Analysis Neil Woodford AIM dog Mereo Pharma, another body blow – insolvent by end January

For some reason, Britain’s most disgraced fund manager held this AIM dog in his Equity Income Fund though the chances of it paying a dividend made my chances of getting lucky with Cheryl Cole look like a nailed down sure fire certainty.  Today there is another body blow, clinical failure, but the real issue, if you do the maths, is looming insolvency.

Neil Woodford Dog Mereo collapses further and spoofs the market (at least, I hope it was a spoof)

Woodford dog Mereo Biopharma, with its “value-enhancing” (according to 31% holder Neil Woodford) merger with Nasdaq’s Oncomed all delivered, has continued to slide: the shares, having been 325p at IPO on AIM in 2016 and having been over 160p up until completion of the merger have now collapsed to just 81p.

Neil Woodford Dog Mereo – FY18 results…..oh dear

Oh dear oh dear oh dear. I commented at the weekend HERE that AIM- and now Nasdaq-listed Mereo Biopharma (AIM: MPH, Nasdaq: MREO) has FY18 results due this Monday, following Mereo’s merger with Oncomed on Nasdaq. Duly reported, how’s that extended cash runway doing?

Neil Woodford dog Mereo Biopharma completes “value-enhancing” merger...er....

Mereo Biopharma (MPH) is a typical Woodford dog: until a few days ago Neil had just shy of 42% of the equity in this cash-guzzling enterprise, which joined the AIM Casino back in June 2016 with a valuation of £142 million and a lofty share price of 325p, having raised £14.8 million, plus a convertible loan note worth another three million.

Mereo - the worst Primary Bid offer ever flops disastrously - it says it was a success. Whatever.

On Saturday Cynical Bear asked if the Mereo Pharma (MPH) offer at 300p via Primary Bid was its worst ever? The answer, notwithstanding stiff competition from uber dogs such as Toople (ROOP) was clearly YES!. And the placing has flopped. Living in la la land Mereo says it was "successful". Like fuck it was. You lie Mereo!

Mereo BioPharma (#MPH) – raises just £0.15m via PrimaryBid offer

Mereo Biopharma – Is this the worst PrimaryBid offering ever?

I had to laugh last night when I saw PrimaryBid’s pre-Bank Holiday offer to the likes of you and me -  Mereo Biopharma (MPH) - as although there’s some stiff competition, I think this must the worst  deal offered up to-date and, in fact, worse than the other offer of a lifetime that I’m currently working out how to avoid, namely dinner at the in-laws during the Champions League final!

Mereo Biopharma (#MPH) raises £14.8m and joins AIM Casino with £142m valuation. Whatever